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Primary Prevention of Allergic Diseases: Current Concepts
and Mechanisms
Kerstin Gerhold, MD, Yasemin Darcan, MD, and Eckard Hamelmann, MD
Atopic diseases, the new ‘‘epidemic of the twenty-first century’’ and a central health problem of industrial nations, call for the
development of innovative primary prevention strategies. The present review provides an overview of current experimental and
immunomodulatory procedures and their underlying mechanisms.
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A
s a new ‘‘epidemic of the 21st century’’
1 causing
growing health problems, particularly in industrialized
countries, atopic diseases such as hay fever, bronchial
asthma, and atopic dermatitis call for the development of
innovative primary prevention concepts (Figure 1, Table 1).
Pathophysiology of allergic diseases is based on extreme
T helper (Th)2 immune responses to commonly harmless
environmental antigens. The key cytokines interleukin
(IL)-4 and IL-13 induce immunoglobulin (Ig) class switch
in B cells, leading to excessive IgE production with
subsequent mast cell activation and mediator release, and
IL-5 contributes to development of eosinophilic inflam-
mation and enhances mucus production of the airway
epithelia (recently reviewed by Coffmann
2). The reasons
for dysregulation and the resulting imbalance in cellular
immune responses on allergens are still not certainly
identified. Genetic predisposition, especially gene–gene
interactions,
3 seems to be a fundamental factor but does
not explain the extensive increase in the incidence and
prevalence of atopic diseases within the last 40 years.
Numerous environmental triggers might account for this
increase, such as altered climate conditions with increasing
global warming, resulting in lengthened pollen seasons and
thus increased exposure to environmental allergens, or
lifestyle factors, such as improved hygiene.
4 Simple
allergen avoidance for primary prevention of allergy
appeared not to be practical or sufficient,
5 and present
antiphlogistic therapies with antihistamines or steroids just
diminish symptoms for a short time but potentially cause
side effects and are not curative.
6
New immunomodulatory strategies aim to support
naturally occurring regulatory mechanisms that may protect
against predominant Th2 immune responses and maintain
the immunologic balance, thus preventing the development
of allergen sensitization as the first step of the atopic march
in high-risk children.
7 Most of these new methods are
currently under experimental investigation, and only a few
have already been employed in humans. The present review
provides an overview of these various immunomodulatory
strategies and their principal mechanisms.
Th1/Th2 Concept: Center of Immunomodulatory
Prevention Strategies
Polarization of the adaptive cellular immune response is
based on antigen presentation by dendritic cells (DCs) or
other antigen-presenting cells (APCs) that leads to
differentiation of naive CD4
+ T cells into Th1 or Th2
effector cells. Immature skin or mucosa-associated DCs
phagocytize a foreign antigen on its entry site and migrate
via blood and lymph to secondary lymphatic organs while
they are differentiating to mature APCs. In secondary
lymphatic organs, DCs create an immunologic synapse
with naive CD4
+ T cells: they present the phagocytized and
processed antigen in a complex with major histocompat-
ibility complex molecules to the respective T-cell receptor,
secrete cytokines, and express costimulatory molecules that
interact with specific coreceptors on the T cell.
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stromal lymphopoietin (TSLP),
8 which is produced by
epithelial cells, of the costimulatory proinflammatory
molecule OX40 ligand,
9 and of IL-4, allergen-induced
activation of mature CD8a
2 myeloid DCs of the lungs
initiates differentiation of naive CD4
+ T cells to Th2 cells. IL-
4 activates cytoplasmic janus kinases (JAKs) 1, 2, and 3
through its two T-cell receptor subsets that phosphorylate
tyrosine rests and subsequently activate transcription factor
signal transducer and activator of transcription (STAT)6.
STAT6 mediates induction of transcription factor GATA-3.
Bothoftheminitiate transcription ofthe Th2 cytokinesIL-4,
IL-5, and IL-13, most likely through activation of the
respective promoter genes.
10,11
Intracellular pathogens promote mature CD8a
+ plas-
mocytoid DCs to produce IL-12, IL-23, and interferon
(IFN)-c. Binding of IL-12 to the b2-subset of the IL-12R
on CD4
+ T cells activates JAK2 and subsequently STAT4.
STAT4 activates the IFN-c promoter gene, which probably
directly induces production of IFN-c. Further, IL-12 is
able to intensify Th1 immune responses through activa-
tion of mitogen-activated protein kinase (MAPK) p38,
resulting again in STAT4 activation. IFN-c, which is
secreted by mature plasmocytoid DCs and by T cells in an
autocrine pathway, activates the transcription factors
STAT1 and subsequently T box expressed in T cells (T-
bet). As a so-called ‘‘master controller,’’ T-bet promotes
the Th1 immune response indirectly via suppression of
GATA-3.
12
In terms of the dichotomy of the adaptive cellular
immune response first described by Mosmann and collea-
gues,
13theTh1 immuneresponseactsasanaturalantagonist
of the Th2 immune response. Thus, various prevention
concepts aim at generation of Th1 effector cells to suppress
Th2 immune responses. At the same time, predominance of
Th1 immune responses is believed to trigger development of
autoimmune diseases such as type 1 diabetes, autoimmune
thyroiditis, or rheumatic diseases. But as recently shown, the
rise of autoimmune inflammation depends on IL-17-
producing Th17 cells. In contrast to former assumptions,
Th17 cells do not develop from precursor Th1 cells but
represent a third Th cell population, which is directly
induced by DCs producing IL-23 and inhibited by both
cytokines, IL-4 and IFN-c. Therefore, IL-4 and IFN-c
prevent development of autoimmune diseases, which has
also been increasing within the last 40 years.
14,15 Use of Th1
cytokines (IFN-c, IL-12) in clinical surveys was ineffective or
showed high rates of side effects.
16
Modulation of the Signal Transduction Cascade by
Inhibition of Transcription Factors
Specific blockade of Th2 effector cytokines by monoclonal
antibodies is used to treat already existing allergic diseases.
Figure 1. Allergen-induced immune
response and new concepts for pri-
mary prevention. Allergen-mediated
activation of antigen-presenting cells
(APCs) induces allergen-specific T
helper (Th)2 cells. Th2 cells produce
Th2 cytokines, resulting in increased
production of immunoglobulin E by B
cells, activation of chemokines and
adhesion molecules, and, finally, aller-
gic inflammation. In round brackets,
targets for primary prevention con-
cepts, as shown in Table 1.
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the distinct transcription factors STAT6 and GATA-3 for
primary prevention of allergen-induced sensitization and
Th2 immune responses. Antiviral activity of imidazoquin-
olines such as imiquimod is based on inducing Th1
immune responses in macrophages and DCs that was
exploited to antagonize Th2 immune responses. In our
mouse model of allergen-induced airway inflammation,
local application of the imiquimod derivative resiquimod
via the airways after allergen sensitization but prior to
airway allergen challenges inhibited development of
eosinophilic airway inflammation and airway hyperreac-
tivity that was associated with a shift from a predominant
Th2 immune response toward a predominant Th1
immune response.
17 Induction of T-bet and suppression
of GATA-3 were recently described to be the fundamental
and protective mechanisms of imidazoquinolines.
18
Inhibition of Th2-inducing transcription factors can also
be performed by so-called ‘‘gene silencing,’’ the inhibition
of distinct gene transcription. Oligonucleotide (ODN)
decoys competitively inhibit binding of transcription
factors at the deoxyribonucleic acid (DNA) of specific
promoter genes and therefore inhibit transcription of
respective genes. Indeed, inhibition of STAT6 by means of
ODN decoys did diminish proliferation of murine and
human Th2 cells in vitro
19 and did suppress IgE synthesis
and development of the late-phase inflammatory response
in vivo in a mouse model of atopic dermatitis.
20
Although STAT1 directs Th1 immune responses, it also
supports development of allergen-induced airway inflam-
mation by enhancing expression of the costimulatory
molecule CD40 on APCs and B cells. CD40 interacts with
Table 1. Immunomodulatory Concepts for Prevention of Allergen-Mediated T Helper 2 Immune Response
No. in Figure 1 Principle Target Mechanism Examples
1 Inhibition of Th2
cytokine synthesis
Transcription factors
of Th2 cytokines
Inhibition of synthesis
of transcription factors
on the level of
transcription
Imiquimod/resiquimod
ODN decoys
Inhibition of synthesis
of transcription factors
on the level of
translation
Antisense ODN
siRNA
2 Protein kinases of signal
transduction cascade
Inhibition of signal
transduction cascade
following activation
of TCR and/or
costimulatory receptor
molecules
Inhibitors of ERK, MEK 1/2
Inhibition of signal
transduction cascade
on the way to synthesis
of costimulatory
receptor molecules
Inhibitors of ICOS-inducing
protein kinases
3 Induction of Th1
immune response
Pattern recognition
receptors on APCs
Activation of TLR-2 Mycobacterial antigens
Activation of TLR-9 CpG motifs
Activation of TLR-4 Lipopolysaccharides
? Probiotics
4 Induction of tolerance-
inducing Tregs
Transcription factors
of regulatory cytokines?
Induction of Foxp3,
TGF-b and IL-10
SIT
Parasites
APC 5 antigen-presenting cell; CpG 5 cytosine guanine dinucleotide; ERK 5 extracellular signal-regulated protein kinase; Foxp3 5 forkhead box protein 3;
ICOS 5 inducible costimulator; IL 5 interleukin; ODN 5 oligonucleotide; siRNA 5 small interfering ribonucleic acid; SIT 5 allergen-specific immune
therapy; TCR 5 T-cell receptor; TGF 5 transforming growth factor; Th 5 T helper; TLR 5 Toll-like receptor; Treg 5 regulatory T cell.
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cytokines. In accordance, intranasal application of STAT1-
i n h i b i t i n gO D Nd e c o y sd i dd i m i n i s hT h 2c y t o k i n e
production and expression of IL-4-dependent vascular cell
adhesion molecule (VCAM)-1 on endothelial cells, which
is known to promote leukocyte infiltration of the airways
and therefore did prevent development of allergen-
induced airway disease in sensitized mice.
21 Further
experimental studies are required to analyze the effects of
STAT1 on allergen sensitization.
Competitive inhibition of production of transcription
factors and cytokines at the ribonucleic acid (RNA) level
might also result in diminished Th2 cytokine production
(recently reviewed by Popescu
22). Specific antisense ODNs
containing 15 to 20 ODNs activate ribonuclease H, which
splits the RNA rest out of DNA-RNA double strands and
therefore degrades target messenger RNA, or antisense
ODNsinhibittranslationviastericblockadeofribosomes. In
fact, in a mouse model, local application of specific antisense
ODNs did diminish expression of GATA-3, which resulted
in dramatically suppressed Th2 cytokine production and
allergen-mediated airway inflammation.
23 In contrast,
suppression of STAT6 by antisense ODN decoys showed
divergent therapeutic effects in vitro and in vivo.
24,25
Compared to antisense ODN decoys, the small interfer-
ing ribonucleic acid (siRNA) technique promises to be more
efficient. Specific endonucleases, so-called ‘‘dicer enzymes,’’
split long double-strand RNA into siRNA containing 21 to
23 nucleotides. Alternatively, synthesized siRNAs are
commercially available. siRNAs are integrated into the
RNA-induced silencing complex (RISC), which contains
helicases, endonucleases, and exonucleases. RISC degradates
specifically target RNA molecules by means of the antisense
strand of siRNA to interrupt protein biosynthesis.
26 Trian
and colleagues recently showed that siRNA inhibited
expression of mast cell protease-activated receptor (PAR)-2
in human airway smooth muscle cells in vitro.
27 PAR-2 is
probably involved in activating airway smooth muscle cells;
therefore, it might provoke airway obstruction and hyper-
reagibility in bronchial asthma.
27 At present, we are
analyzing in our mouse model of allergen-induced airway
inflammation whether local application of siRNA suppresses
expression of STAT6 and GATA-3 and subsequently inhibits
allergen-induced airway inflammation.
Modulation of the Signal Transduction Cascade by
Inhibition of Protein Kinases
Receptor-dependent cytoplasmatic protein kinases are
responsible for phosphorylation and activation of tran-
scription factors; thus, they fundamentally control differ-
entiation of naive CD4
+ T cells in Th1/Th2 effector cells
and synthesis of mediators, inducing development of
allergen-induced inflammation. Inhibition of JAKs, which
take part in differentiation of both Th1 and Th2 effector
cells, might result in unspecific effects. In contrast, the
extracellular signal-regulated protein kinase (ERK), which
b e l o n g st ot h eM A P K ,m e d i a t e sa c t i v a t i o no ft h e
eosinophilic IL-5R and eotaxin-R, initiating accumulation
and degranulation of eosinophils in the airways.
28,29
Systemic application of a specific inhibitor (UO126)
inhibited ERK through competitive inhibition of upstream
MAPK/ERK-kinase (MEK)1/2 and suppressed allergen-
induced IgE production, VCAM-1 expression in lungs,
mucus production in the airway, and airway hyperreactiv-
ity in mice.
30
Th2-cell differentiation requires further costimulatory
signals, particularly interactions between CD28 and induc-
ible costimulator (ICOS) on T cells on the one hand and
their ligands CD80/86 and ICOS-L on DCs, B cells, and
other APCs on the other hand.
31 ICOS acts through
activation of MAPK, ERK, and Jun NH2-terminal kinase
(JNK). Systemic application of U0126 or SP600125 selec-
tively inhibited ERK or JNK, which, respectively, prevented
local allergen-mediated Th2 immune responses and eosino-
philic airway inflammation in allergen-sensitized mice
following airway allergen challenges.
32 ICOS transcription
is regulated by two independent pathways, the Fyn-
calcineurin-NFATc2 pathway and the MEK2-ERK1/2 path-
way.
33 Thus, expression of the proinflammatory costimula-
tory molecule ICOS might be diminished by inhibiting
members of these pathways, such as the protein kinase Fyn,
the transcription factor nuclear factor of activated T cell
(NFAT)c2 or MEK2/ERK1/2. Methods might include direct
kinase inhibitors or ‘‘gene silencing’’ techniques.
Modulation of Immune Responses through
Stimulation of Innate Immunity
DC activation by foreign antigens represents the first step
on the way toward T-cell activation and maturation and
therefore the first step on the way toward allergen
sensitization. Most allergens are immunologic inert
proteins that typically do not induce inflammatory
responses but allergen-specific tolerance. However, the
presence of so-called ‘‘danger signals’’ such as proteolytic
enzyme activity of allergens themselves or microbial
antigens leads to DC activation. Particularly, DCs express
pattern recognition receptors (PPRs) such as Toll-like
receptors (TLRs) for microorganism-associated molecular
108 Allergy, Asthma, and Clinical Immunology, Volume 3, Number 4, 2007patterns (MAMPs) that are invariant and consistent
molecular structures of bacteria and other microorgan-
isms. PPR activation induces MAMP-dependent signal
transduction and activation of transcription factor nuclear
factor (NF)-kB and of MAPK, followed by transcription of
proinflammatory cytokines such as tumour necrosis factor
(TNF)-a, IL-6, und IL-12 and expression of costimulatory
molecules such as CD40 and CD80/CD86 (recently
reviewed by Kaisho and Akira
34). Regular development
of the immune system and the balance of adaptive Th1/
Th2 immune responses is probably based mainly on
natural exposition to microbial antigens as TLR ligands via
the gastrointestinal tract, skin, and airways or on several
infectious diseases during early infancy and childhood. A
variety of immunomodulatory prevention concepts
attempt to reconstitute the natural balance of the adaptive
immune response by specific activation of PPRs by means
of microbial antigens.
Mycobacterial Antigens
Mycobacterial antigens such as lipoproteins activate TLR-2
in complex with TLR-1 and TLR-6 or TLR-4; induce
production of IL-12, TNF-a, IL-10, and IL-15; and initiate
development of Th1 effector cells.
35 In numerous mouse
models, vaccination with live or inactivated pathogenic or
apathogenic Mycobacteria prevented development of aller-
gen-mediated sensitization and airway inflammation.
36–39
Recent clinical trials showed a therapeutic effect such as
subcutaneous injection of heat-inactivated Mycobacteria
bovis bacille Calmette Gue ´rin on pre-existing asthma in
adults
40 or intradermal application of Mycobacterium
vaccae on moderate or severe atopic eczema in children.
41
Nevertheless, primary preventive effects of Mycobacteria on
atopic diseases in humans need to be further investigated.
CpG motifs
Unmethylated cytosine guanine dinucleotides (CpGs) are
common components of prokaryotic bacterial or viral
DNA; they are also synthetically produced (CpG motifs).
CpGs are incorporated by DCs via endocytosis; they bind
and activate cytosolic TLR-9 and induce activation of NF-
kB, followed by secretion of type I interferons, IL-12, IFN-
inducing protein 10, and other cytokines and chemokines.
The resulting innate Th1 immune response is short and
limited to proliferating T cells; it is not able to modulate
memory Th2 cells.
34 Further, CpG motifs activate the
tryptophan-degrading enzyme indolamine-2,3-deoxygen-
ase (IDO) via the STAT1 pathway in CD19
+ DCs.
Intracellular lack of tryptophan and its metabolites causes
toxic and other unknown effects, causing diminished T-
cell proliferation and immune suppression. Thus, CpG
motifs support development of regulatory T cells
(Tregs).
42 Accordingly, they induced Th1 cells and/or
Tregs that inhibited Th2 immune responses and prevented
allergen-induced sensitization and airway inflammation in
many animal models and clinical trials (lately reviewed by
Racila and Kline
43). At present, CpG motifs are more and
more used as adjuvants for allergen-specific immune
therapy (SIT), even in humans. CpG motifs are conjugated
with allergens; local or systemic administration of these
conjugates generates allergen-specific long-lasting adaptive
Th1 immune responses, induces Tregs, and probably also
stimulates memory Th2 cells to shift into Th1 effector cells
after further allergen contacts.
44
Lipopolysaccharides
The so-called ‘‘farming effect’’ belongs to the best-
described environmental factors that are associated with
a diminished risk of atopic diseases.
45 It is based on
intensive exposure to organic dust and thus to a variety of
microbial antigens in stables on farms from early infancy
on. Peters and colleagues recently confirmed protective
properties of organic dust from stables with regard to
allergen-mediated sensitization and airway inflammation
in a mouse model.
46 Several experimental studies in mice
and humans have analyzed, in particular, the immuno-
modulatory allergy-preventing effects of lipopolysacchar-
ides (LPSs), the cell wall component of gram-negative
bacteria and an important ingredient of organic dust. In
serum, LPSs bind their soluble receptors lipopolysacchar-
ide-binding protein (LBP) and CD14 and activate TLR-4;
LBP and CD14 catalyze TLR-4 activation.
TLR-4 activation activates through the intracellular
adaptor molecule MyD88-associated cytoplasmatic protein
kinases such as IL-1 receptor-associated kinase (IRAK)4
and others (TRAF6, TAK1, IKKb), which leads to IkB
phosphorylation and finally to NF-kB activation.
34
Epidemiologic studies suggested that polymorphisms for
CD14 and TLR-4 resulting in reduced responsiveness of
DCs on LPSs are associated with an increased risk of
developing atopic diseases.
47 In our own work in adult
mice, local and systemic application of LPSs later
suppressed allergen-mediated sensitization and airway
inflammation in an IL-12-dependent way.
48 In neonatal
mice, repetitive exposure to simple aerosolized LPSs did
not prevent subsequent allergen sensitization, but in
combination with allergen-induced mucosal tolerance,
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might diminish the susceptibility of organisms to a variety
of environmental allergens.
49
Further, Wang and McCusker showed in a similar
model that repetitive exposure of neonatal mice to LPS
and ovalbumin led to development of tolerance-inducing
Tregs in later sensitized mice.
50 Prenatal initiated and
postnatal continued exposition to aerosolized LPS inhib-
ited development of allergen-induced sensitization and
airway inflammation in the offspring that was associated
with a shift from a predominant Th2 immune response
toward a predominant Th1 immune response and was
most likely mediated by upregulation of the LPS receptors
LBP, CD14, TLR-2, and TLR-4, as well as of the Th1
regulatory transcription factor T-bet.
51
At present, we are investigating in a prospective,
double-blind, placebo-controlled, interventional trial in
high-risk infants the potentially preventive effect of orally
given apathogenic Escherichia coli strains on the develop-
ment of atopic dermatitis within the first 7 months of life.
Probiotics
Colonization of the gut by commensal microbes within the
first months of life represents the first and probably most
important stimulus for the development of the gut-
associated immune system, the largest organ-associated
immune system. Composition of the gut flora might
influence allergen sensitization decisively since epidemio-
logic observations demonstrated that countries with a high
or low prevalence of allergic diseases and atopic and non-
atopic individuals showed different microbial strains in the
gut,
52 and oligosaccharides (prebiotics) might prevent
allergies by supporting the growth of distinct microbes.
53
Thus, at present, animal models and clinical trials are used
to elucidate the potentially preventive effects of probiotics,
living apathogenic bacteria with health-supporting effects.
Indeed, in a prospective clinical trial, Lactobacillus
rhamnosus, which was given orally during pregnancy and
further on during the first months of life, inhibited
manifestation of atopic dermatitis in high-risk infants.
54
The probiotics employed are lactobacilli and bifidobacteria
in particular, which are acid resistant and adherent to gut
mucosa and further colonize the gut. The mechanisms are
unclear. In neonatal mice, probiotics induced development
of transforming growth factor (TGF)-b producing T cells,
resulting in diminished IgE and Th2 cytokine produc-
tion
55; another clinical trial showed enhanced Th2-
antagonizing IFN-c production.
56 Increased permeability
of gut epithelia for allergens, which was shown for children
with atopic dermatitis, is also suggested to cause allergen
sensitization.
Distinct gut bacteria produce toxic metabolites such as
D-lactic acid or acetaldehyde, which inhibit adenosine
triphosphate–dependent synthesis of the epithelial cyto-
skeleton, resulting in defective barrier functions. In young
infants, these metabolites accumulate even more as a
consequence of immature degrading enzymes. Probiotics,
which do not induce toxic metabolites, might provide a
balance of the gut flora and compensate for toxic effects,
such as breast milk.
57
Modulation of Immune Responses by Tolerance
Induction
The immune system physiologically does not respond to
self-molecules or harmless environmental antigens.Tregs are
thought to mediate this phenomenon of antigen-specific
tolerance. Natural Tregs develop in the thymus, express
constitutively CD25 (IL-2Ra chain) and the transcription
factorforkheadboxprotein3(Foxp3),andactinanantigen-
independent manner immunosuppressively. In the periph-
ery, a xenogeneic group of adaptive antigen-specific Tregs
(aTregs) develop from still unknown (CD25
2) precursor
cells in response to foreign antigens. ATregs become CD25
+
during their development;onlysomeofthemexpress Foxp3,
especially following activation through CD3, CD28, and
TGF-b.
58 IL-2 is a decisive growth factor for Tregs; CD28
acts as a costimulatory factor
58; Foxp3 forms a complex with
histone acetyltransferases, histone deacetylases, and chro-
matin remodeling factors, and inhibits acetylation of
histones that results in stopping of DNA transcription as
the first step in T-cell proliferation and differentiation.
58
Akdis and colleagues first described diminished numbers of
Tregs in atopic patients.
59 Thus, an imbalance between Th2
(andTh1)cells on the one handand Tregsontheotherhand
might be responsible for the development of atopic diseases,
and immunomodulatory prevention concepts focus on
induction of Tregs. The Foxp3 complex itself might be a
target; inhibitory factors of histone deacetylases mediate
stopping of the cell cycle, diminish cytokine expression, and
increase apoptosis, but low target specificity causes serious
side effects. At present, more specific Foxp3-associated
molecular targets are being extensively investigated to
modulate the effects of the Foxp3 complex.
58
Myeloid and plasmocytoid, immature and mature DCs
induce aTregs by producing anti-inflammatory cytokines,
particularly IL-10. In a positive feedback mechanism, IL-10
from DCs and IL-10 and TGF-b produced by Tregs initiate
the development of tolerogenic DCs.
60 Further, Tregs
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CD80/CD86 on maturing DCs. Thus, antigen-activated
Tregs are able to inhibit sufficient presentation of further
antigens by the same DC.
61 Allergens in higher doses than
required only for allergen sensitization activate CD8
2
myeloid DCs that initiate differentiation of aTregs through
their costimulatory molecule ICOS-L and transient
production of IL-10.
At present, allergen-specific immunotherapy (SIT)
representstheonlyestablishedcurativebutmerelysecondary
preventive and antigen-specific therapy for allergic diseases.
Subcutaneous applications of increasing doses of allergen
over 3 to 5 years induce allergen-specific Foxp3
+ Tregs,
which express surface molecules such as cytotoxic T-
lymphocyte antigen (CTLA)-4 und programmed death
(PD)-1 and secret IL-10 and TGF-b. Therefore, these cells
induce a lifelong allergen-specific tolerance through inten-
sive immunosuppressive and anti-inflammatory proper-
ties.
62 CTLA-4 of these Tregs also activates mature DCs via
CD80/CD86, which consequently express IDO and may
suppress T-cell functions the other way round.
61
Following mucosal allergen exposition via the airways,
plasmacytoid DCs are activated, which generate Tregs and
cause allergen-specific mucosal tolerance in mice.
49,62 Our
own preliminary data showed that repetitive exposures of
pregnant mice to aerosolized allergen consistently pre-
vented later allergen sensitization and airway inflammation
in the offspring associated with diminished allergen-
specific T-cell responses in vitro and development of
IFN-c-producing T cells (unpublished data).
Heat-inactivated Listeria monocytogenes, which was
given as an adjuvant together with an allergen, activated
mature CD8
+ plasmacytoid DCs to produce IL-10 and IL-
12, resulting in development of IL-10- and IFN-c-
producing allergen-specific Tregs. These Th1-like Tregs
expressed Foxp3 and later prevented allergen-mediated
airway hyperreactivity in mice.
63
Modulation of Immune Responses by Parasites
During their acute infectious state, helminthes secrete
proteases that act as virulent factors and induce a strong
Th2 immune response and a massive unspecific IgE
production in the host. Further, proteases act as ‘‘danger
signals’’ and activate DCs that might promote allergen
sensitization.
64 Additionally, parasite antigens such as
tropomyosins might show cross-reactivity with allergens,
resulting in enhanced allergen sensitization.
65 In contrast,
the anti-inflammatory effects of helminthes in the chronic
state might be responsible for inverse correlations between
parasitic and allergic diseases.
66 The anti-inflammatory
property of helminthes is more and more used for
immunomodulatory therapeutic and prevention concepts,
although the underlying mechanisms have not been
clarified. Both DCs and APCs, as well as CD4
+ T cells,
might play a key role. According to experimental data,
helminthes induce Foxp3
+ IL-10- and TGF-b-producing
Tregs that inhibit development of allergen-mediated
sensitization and airway inflammation in mice.
67,68
Helminthes also induce CD1
+ natural killer T cells, a
subgroup of T cells that express natural killer cell markers
and produce immunoregulatory cytokines.
69
Filarias produce the anti-inflammatory molecule ES62,
which suppresses B-cell activation and proliferation by
interaction with the signal transduction cascade of the B-cell
antigen receptor and inhibits production of proinflamma-
tory cytokines by interaction with the TLR signal transduc-
tion cascade.
70 Further, oligosaccharides with
immunomodulatory capacities such as lacto-N-neotetraose,
which helminthes express on their surface, induce a
subgroup of natural Gr1
+CD11b
+F4/80
+ suppressor cells,
immature myeloid cells that produce IL-10 and TGF-b and
inhibit proliferation of naive CD4
+ T cells via IFN-c-
dependent cell–cell contact.
71 Development of derivatives of
these natural immunomodulatory molecules might be of use
for primary prevention against allergen-mediated diseases.
Conclusion
Enormous progress in clarifying the genetic and molecular
mechanisms of allergic sensitization allows the develop-
ment of novel immunomodulatory strategies aimed at
primary prevention of allergen-mediated diseases. These
are based either on the inhibition of their most relevant
pathogenetic elements or in the induction of natural
immunoregulatory mechanisms. The achievement of
balance in adaptive immune responses against allergens
represents the common goal of novel preventive concepts.
Ultimately, these specific and curative treatment proce-
dures shall remove symptomatic and often unspecific
therapies with potentially severe side effects. The first
promising experimental data are giving hope but need to
be carefully validated in clinical trials for practicability,
safety, and efficiency.
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